Last reviewed · How we verify

Centro Medico Nacional La Raza, IMSS — Portfolio Competitive Intelligence Brief

Centro Medico Nacional La Raza, IMSS pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Diazepam Injectable Solution Diazepam Injectable Solution marketed Benzodiazepine GABA-A receptor Neurology, Psychiatry, Critical Care

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ajenat Pharms · 1 shared drug class
  2. Assaf-Harofeh Medical Center · 1 shared drug class
  3. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 shared drug class
  4. B.P. Koirala Institute of Health Sciences · 1 shared drug class
  5. Bausch Health · 1 shared drug class
  6. Chang Gung Memorial Hospital · 1 shared drug class
  7. Consorci Sanitari de l'Anoia · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centro Medico Nacional La Raza, IMSS:

Cite this brief

Drug Landscape (2026). Centro Medico Nacional La Raza, IMSS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centro-medico-nacional-la-raza-imss. Accessed 2026-05-17.

Related